论文部分内容阅读
目的观察探讨伏立康唑治疗血液系统疾病并发肺部侵袭性真菌感染的效果及不良反应。方法回顾性分析13例血液系统疾病合并肺部侵袭性真菌感染患者的临床资料,7例患者初治即使用常规剂量伏立康唑,5例在氟康唑无效情况下改用伏立康唑,1例患者联合使用卡泊芬净及伏立康唑。结果 13例患者有效10例(其中治愈7例,改善3例),无效2例,死亡1例。副反应:肝功能异常2例,1例为谷丙转氨酶及谷氨酰转肽酶轻度升高,1例出现轻度黄疸,2例出现一过性低钾血症,未出现一次性视觉障碍,不需要停止伏立康唑进行治疗。肺部侵袭性真菌感染患者有效率为76.9%。结论伏立康唑治疗血液系统疾病并发肺部侵袭性真菌感染安全有效,副作用小。
Objective To investigate the effect and adverse reactions of voriconazole in the treatment of hematologic diseases complicated with pulmonary invasive fungal infection. Methods The clinical data of 13 patients with hematologic diseases complicated with invasive fungal infection in the lung were retrospectively analyzed. Of the 7 patients, voriconazole was used in the initial treatment, voriconazole was not used in 5 patients, and voriconazole was used in 1 patient. Caspofungin and Voriconazole. Results Of the 13 patients, 10 were effective (7 were cured and 3 were improved), 2 were ineffective and 1 died. Side effects: 2 cases of abnormal liver function, 1 case of alanine aminotransferase and glutamyl transpeptidase slightly elevated, 1 case of mild jaundice, 2 cases of transient hypokalemia, no one-time visual Obstacle, do not need to stop voriconazole for treatment. The effective rate of lung invasive fungal infection was 76.9%. Conclusion Voriconazole is safe and effective in the treatment of hematologic diseases complicated with pulmonary invasive fungal infection with small side effects.